[go: up one dir, main page]

DK3566703T3 - Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol - Google Patents

Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol Download PDF

Info

Publication number
DK3566703T3
DK3566703T3 DK19168102.2T DK19168102T DK3566703T3 DK 3566703 T3 DK3566703 T3 DK 3566703T3 DK 19168102 T DK19168102 T DK 19168102T DK 3566703 T3 DK3566703 T3 DK 3566703T3
Authority
DK
Denmark
Prior art keywords
imidazol
methylphenyl
methanol
ethyl
pharmaceutical compositions
Prior art date
Application number
DK19168102.2T
Other languages
English (en)
Inventor
Daniel W Gil
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3566703T3 publication Critical patent/DK3566703T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19168102.2T 2009-02-13 2010-02-12 Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol DK3566703T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15249409P 2009-02-13 2009-02-13
EP17174959.1A EP3241553B1 (en) 2009-02-13 2010-02-12 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Publications (1)

Publication Number Publication Date
DK3566703T3 true DK3566703T3 (da) 2021-07-05

Family

ID=42083967

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19168102.2T DK3566703T3 (da) 2009-02-13 2010-02-12 Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Country Status (9)

Country Link
US (3) US20110301214A1 (da)
EP (3) EP3566703B1 (da)
JP (1) JP2012518007A (da)
AU (1) AU2010213580A1 (da)
CA (1) CA2752148A1 (da)
DK (1) DK3566703T3 (da)
ES (3) ES2733905T3 (da)
HK (1) HK1246204B (da)
WO (1) WO2010093930A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
EP2640382B1 (en) 2010-11-16 2016-10-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
JP2014521643A (ja) * 2011-07-22 2014-08-28 アラーガン インコーポレイテッド 眼の中枢視覚投影によって媒介される視覚障害を治療するためのα−2アドレナリン調節剤
AU2012340806B2 (en) * 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
EP4642453A1 (en) * 2022-12-27 2025-11-05 Alceptor Therapeutics, Inc. (s)-(3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol for treatment of agitation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
EP2640382B1 (en) 2010-11-16 2016-10-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases

Also Published As

Publication number Publication date
ES2733905T3 (es) 2019-12-03
EP2395999B1 (en) 2017-09-13
EP3566703A1 (en) 2019-11-13
EP3241553B1 (en) 2019-04-10
EP3566703B1 (en) 2021-04-07
CA2752148A1 (en) 2010-08-19
AU2010213580A1 (en) 2011-09-08
US20160038466A1 (en) 2016-02-11
US20150080445A1 (en) 2015-03-19
WO2010093930A1 (en) 2010-08-19
HK1246204B (en) 2020-02-07
ES2880578T3 (es) 2021-11-24
US9555021B2 (en) 2017-01-31
JP2012518007A (ja) 2012-08-09
ES2649018T3 (es) 2018-01-09
EP2395999A1 (en) 2011-12-21
EP3241553A1 (en) 2017-11-08
US9193690B2 (en) 2015-11-24
US20110301214A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
BRPI0914746A2 (pt) composições fungicidas
DK2080901T3 (da) Vindmølle-vindmålings-kompensation
DK2285411T3 (da) Nikotintabletsammensætninger
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2258369A4 (en) PLASTER WITH MEDICAMENT PLASTER
BRPI0923433A2 (pt) Síntese de compostos fucosilados
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0918602A2 (pt) composto (i)
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0915427A2 (pt) composição farmacêutica
DK3338777T3 (da) Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
BR112012002336A2 (pt) compostos aza-heterocíclicos
EP2280032A4 (en) PHOTOPOLYMERIZABLE COMPOSITIONS
BRPI0820198A2 (pt) composições farmacêuticas
DK3566703T3 (da) Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
DK2774612T3 (da) 4-Methylpyrazolformuleringer
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan
IL226384A0 (en) Pharmaceutical preparations containing (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
EP2379762A4 (en) CERMET
PT2376075E (pt) Formulações nasais de metoclopramida
BRPI0907824A2 (pt) Ingrediente de oligossacarídeo
EP2154259A4 (en) CERMET